NASDAQ$ASRT

Assertio Holdings Inc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

Assertio's Q4 2022 financial performance was marked by a 55% increase in net product sales and a significant rise in GAAP net income, driven by a tax benefit and strong Indocin sales.

Assertio Holdings, Inc. reported strong financial results for the fourth quarter and full year ended December 31, 2022. Net product sales increased by 55% in the fourth quarter, and GAAP net income saw a substantial increase due to a tax benefit. The company's strategic actions and acquisitions contributed to the positive change in the business.

  • Net product sales increased by 55% to $49.9 million, driven by Indocin, Otrexup, and Sympazan sales.
  • GAAP net income increased to $88.6 million, primarily due to an $80.4 million tax benefit.
  • Adjusted EBITDA increased to $33.4 million, driven by additional net product sales.
  • Cash and cash equivalents at year-end were $64.9 million, reflecting cash flow from operations partially offset by asset purchase payments.

Headline financials

Total Revenue

$50.4M

Previous: $33.3M+51.1%
EPS (adj)

$0.32

Previous: $0.10+220.0%
Adjusted EBITDA

$33.4M

Previous: $17.8M+87.6%
Capital Expenditures

$274K

Previous: $53K+417.0%
Free Cash Flow

$26.7M

Previous: $4.08M+554.7%
Net Income

$88.6M

Previous: $4.61M+1823.6%
Operating Income

$10.6M

Previous: $7.98M+33.0%
Gross Profit

$44.3M

Previous: $28.4M+55.9%
Cash & Equivalents

$64.9M

Previous: $36.8M+76.3%
Total Assets

$414M

Previous: $327M+26.8%
Stock-Based Comp

$2.39M

Previous: $949K+151.6%

Revenue & EPS history

Assertio · Revenue · Quarterly

$50.4M

Q4 2022+51.1%vs Q4 2021
Beat estimate in 11 of 14 quarters(79%)
ActualEstimate

Revenue by segment

Assertio · $40.1M total across 1 segment · Q2 2023

  • Net Product Sales
    $40.1M

Forward guidance

Assertio anticipates revenue in the first quarter of 2023 to be between $36.0 million to $38.0 million, reflecting typical seasonality and the loss of Cambia exclusivity. The Company’s full year Adjusted EBITDA guidance includes an initial estimate of the anticipated clinical trial costs in the second half of the year.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

-1.9%

Avg return

Earnings day

-4.4%

Avg return

5 days after

-4.5%

Avg return

30 days after

52%

33 / 64 earnings

Positive

+33.3%

Q3 2021

Best reaction

-46.2%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.5%+4.2%+4.7%
Q4 2025+6.5%+13.6%+53.1%
Q3 2025+13.3%-1.2%-1.2%
Q1 2025-1.8%+8.1%+0.0%
Q4 2024-7.5%-7.7%-20.5%
Q3 2024+0.2%-4.7%+12.9%
Q2 2024-12.8%-14.4%+0.8%
Q1 2024+7.8%-6.8%-2.9%
Q4 2023+10.8%+23.1%-1.1%
Q3 2023-45.5%-53.2%-50.9%
Q2 2023-46.2%-41.0%-39.0%
Q1 2023+20.6%+22.2%-3.8%
Q4 2022+7.9%-15.1%-0.6%
Q3 2022-0.4%+10.4%+38.1%
Q2 2022-4.3%-4.8%-32.6%
Q1 2022+6.2%+37.5%+52.9%
Q4 2021+13.8%-0.5%+56.9%
Q3 2021+33.3%+36.0%+18.4%
Q2 2021-2.3%-3.1%-16.3%
Q1 2021+11.8%-3.9%-11.8%
Q4 2020+4.3%-3.2%-35.1%
Q3 2020-41.8%-40.3%-37.3%
Q2 2020-13.8%-18.1%-23.4%
Q1 2020+1.3%+1.2%+21.3%
Q4 2019-35.1%-29.8%-37.7%
Q3 2019-9.6%-13.3%-14.5%
Q2 2019+1.4%-45.1%-54.2%
Q1 2019-0.4%-10.8%-37.9%
Q4 2018-5.8%-12.7%+26.8%
Q3 2018+6.5%+5.5%-16.3%
Q2 2018-19.0%-23.0%-33.5%
Q1 2018+26.5%+23.5%+10.6%
Q4 2017-11.4%-12.3%-15.0%
Q3 2017+15.4%+30.0%+68.6%
Q2 2017-35.1%-33.3%-37.4%
Q1 2017+2.3%+9.0%-3.1%
Q4 2016+4.7%-0.9%-9.9%
Q3 2016-16.1%-8.0%-12.1%
Q2 2016+5.6%+10.2%+8.7%
Q1 2016-6.2%
Q4 2015-4.1%
Q3 2015+6.7%
Q2 2015-7.2%
Q1 2015-14.1%
Q4 2014+13.4%
Q3 2014-2.7%
Q2 2014+5.5%
Q1 2014-23.5%
Q4 2013+14.8%
Q3 2013-0.5%
Q2 2013+4.0%
Q1 2013-2.8%
Q4 2012+6.2%
Q3 2012+1.5%
Q2 2012-0.5%
Q1 2012+3.2%
Q4 2011+3.3%
Q3 2011-10.4%
Q2 2011+3.1%
Q1 2011-1.2%
Q4 2010+0.6%
Q3 2010-0.2%
Q2 2010+5.2%
Q1 2010-4.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro